On Dec. 22, 2020, Sorrento Therapeutics announced that an Emergency Use Authorization (EUA) Application had been submitted to the FDA for its COVI-STIX rapid diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients.

In testing conducted to date, COVI-STIX had provided results within 15 minutes, with positive detection as quickly as two minutes for patient samples with high viral load.